First Successful Phase 3 Trial of a B7-H3-Targeting Antibody-Drug Conjugate

Risvutatug rezetecan (ris-rez, HS-20093), a B7-H3-targeting antibody-drug conjugate (ADC) developed by Hansoh Pharmaceutical Group (3692.HK) and licensed to GSK (GlaxoSmithKline, GSK), has achieved its primary endpoint of overall survival (OS) improvement in a Phase 3 trial (ARTEMIS-008) in China. The trial evaluated patients with recurrent or progressive small cell lung cancer (SCLC) and demonstrated superior survival benefits compared to standard chemotherapy. This marks the first time a B7-H3 ADC has demonstrated Phase 3 overall survival data, validating its target efficacy. It has the potential to become a new standard of care in the treatment of this difficult-to-treat cancer.

GSK's Accelerated Global Clinical Development and Validation of Strategic Asset

This success validates GSK's strategic foresight in designating risvutatug rezetecan as a Priority Asset. GSK holds exclusive global rights (excluding China) and is currently conducting a global Phase 3 trial ('EMBOLD SCLC-301'), with results expected in 2027. Later this year, it plans to initiate an additional late-stage trial for genitourinary cancers, accelerating global expansion of indications. This clinical success will serve as strong support for future regulatory submissions, including to the U.S. Food and Drug Administration (FDA).

Strong Synergistic Effect with Follow-up Pipeline Asset, Mo-Rez

The success of ris-rez is also driving increased value for GSK's other B7-H4-targeting ADC, mo-rez (HS-20089). Mo-rez demonstrated promising efficacy in a Phase 1 trial in April for platinum-resistant ovarian and endometrial cancers. Based on these results, GSK is accelerating the development of mo-rez, including the early initiation of five late-stage clinical trials, including a global Phase 3 trial, to expand its presence in the gynecological cancer market. With these two innovative ADC assets, GSK is further strengthening its next-generation oncology portfolio.

Resolution of Financial Risk Associated with Multi-Billion Dollar Licensing Agreement

Financially, this success enhances the partnership's value and eliminates investment uncertainty. GSK entered into an agreement with Hansoh for ris-rez, including an upfront payment of $185 million and potential milestone payments of up to $1.525 billion, totaling $1.71 billion. Combined with the $1.57 billion agreement for mo-rez, GSK has committed a total of $3.28 billion to the partnership with Hansoh. The success of the Phase 3 trial mitigates the risk associated with this significant investment and paves the way for a smooth transition to commercialization, royalty payments, and revenue generation.

Competitive Landscape in the Global Small Cell Lung Cancer Market and First-Mover Advantage

The global SCLC market is estimated at up to $9.6 billion by 2025-2026, representing a significant unmet need. Currently, Merck & Co. (MRK) and Daiichi Sankyo's B7-H3 ADC, ifinatamab deruxtecan (I-DXd), are in Phase 3 trials and are strong competitors. Additionally, Amgen's bispecific antibody, Imdelltra, is also in development. However, ris-rez's achievement of demonstrating overall survival improvement in Phase 3 provides it with a significant first-mover advantage in the market.